Bitartrate hydrocodone all forward looking statements are qualified in their entirety by this cautionary statement, and Accentia does not undertake any obligation to revise or update this news release to reflect events or circumstances after the date hereof.
UNION CITY, Calif.

Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Though a generic version of this product is currently being marketed, Andrx was awarded a 180-day period of market exclusivity for a later listed patent. For the development and worldwide commercialization of an innovative hydromorphone product which utilizes ALZA's advanced oral osmotic (OROS(R)) technology designed for the 24-hour management of severe chronic pain.

The DDMAC told the company to discontinue use of advertisements and materials that contain similar violative statements. Carisoprodol is a centrally acting muscle relaxant; bitartrate hydrocodone aspirin, a nonopioid analgesic, relieves pain and inflammation. Forward-looking statements (statements which are not historical facts) in this release are made Bitartrate hydrocodone pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Announced today that it has received clearance from the US Food and Drug Administration (FDA) to market Vicoprofen(R) CIII (hydrocodone bitartrate(a) and ibuprofen tablets, 7. 5 mg/200 mg). Close to 90% of Teva's sales are in North America and Europe. The New Drug Application for Abbott's Vicodin bitartrate hydrocodone cr was submitted to the U. (NASDAQ: HITK) announced today that the US Food and Drug Administration (FDA) has granted an approval to the Company's Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Homatropine Methylbromide Syrup, the generic bitartrate hydrocodone equivalent of Endo Pharmaceuticals' Hycodan[R]. Twenty-eight patients discontinued due to adverse events (3 percent in placebo group, 6 percent in the one-tablet group and 7 percent in the two-tablet group) and nine patients reported serious adverse events (two in each HC/APAP group and five in the placebo group). About Hydrocodone Bitartrate and Acetaminophen Extended Release HC/APAP extended release is an investigational formulation with 12-hour dosing, currently in clinical development for the bitartrate hydrocodone relief of moderate to moderately-severe pain. Despite this medical need, prescription opioid pain medications have well-known risks for abuse, misuse and diversion for illegitimate use. Vicoprofen has been shown bitartrate hydrocodone to have excellent patient acceptance.